Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeeme...

 

 

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 25

 

NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 001-37847

 

MOTIF BIO PLC

The Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

 

125 Park Avenue

25^th Floor

New York, New York 10017

[phone]

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

 

American Depositary Shares each representing 20 Ordinary Shares

 

Ordinary Shares, par value £0.01 per share not for trading, but only in connection with the registration of the American Depositary Shares)

 

Warrants to purchase American Depositary Shares each representing 20 Ordinary Shares

 

(Description of class of securities)

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

☐            17 CFR 240.12d2-2(a)(1)

 

☐            17 CFR 240.12d2-2(a)(2)

 

☐            17 CFR 240.12d2-2(a)(3)

 

☐            17 CFR 240.12d2-2(a)(4)

 

☐            Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.(1)

 

☒            Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Motif Bio Plc certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

 

December 9, 2019		By	/s/ Graham Lumsden		Chief Executive Officer
Date			Name		Title

 

---

(1) Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.